title: Cost-effectiveness of spinal cord stimulation versus coronary artery bypass grafting in patients with severe angina pectoris--long-term results from the ESBY study.
abstract: The present study is a 2-year follow-up of the 104 patients participating in the ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina Pectoris), a randomised prospective study including patients with increased surgical risk and no prognostic benefit from revascularisation. Hospital care costs, morbidity and causes of death after spinal cord stimulation (SCS) and coronary artery bypass grafting (CABG) were assessed, as well as the complication rate of SCS treatment. SCS proved to be a less expensive symptomatic treatment modality of angina pectoris than CABG (p < 0.01). The SCS group had fewer hospitalisation days related to the primary intervention (p < 0.0001) and fewer hospitalisation days due to cardiac events (p < 0.05). The groups did not differ with regard to causes of death. There were no serious complications related to the SCS treatment.
authors.affiliation: Multidisciplinary Pain Centre, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Andréll
authors.forename: O
authors.initials: O
authors.lastname: Ekre
authors.forename: T
authors.initials: T
authors.lastname: Eliasson
authors.forename: C
authors.initials: C
authors.lastname: Blomstrand
authors.forename: M
authors.initials: M
authors.lastname: Börjesson
authors.forename: M
authors.initials: M
authors.lastname: Nilsson
authors.forename: C
authors.initials: C
authors.lastname: Mannheimer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000787:Angina Pectoris / Q000628:therapy; D002423:Cause of Death; D001026:Coronary Artery Bypass / Q000009:adverse effects / Q000191:economics*; D003362:Cost-Benefit Analysis; D004599:Electric Stimulation Therapy / Q000009:adverse effects / Q000191:economics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D013548:Sweden; D013673:Technology Assessment, Biomedical / Q000191:economics